The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice
Open accessAbstract
BACKGROUND: Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result. Today's TB treatment, which dates back to the 1970s, is long and burdensome, requiring at least 6 mo of multidrug chemotherapy. The situation is further compounded by the emergence of multidrug-resistant TB (MDR-TB) and by the infection's lethal synergy with HIV/AIDS. Global health and philanthropic organizations are now pleading for new drug interventions that can address these unmet needs in TB treatment. METHODS AND FINDINGS: Here we report OPC-67683, a nitro-dihydro-imidazooxazole derivative that was screened to help combat the unmet needs in TB treatment. The compound is a mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against TB, including MDR-TB, as shown by its exceptionally low minimum inhibitory concentration (MIC) range of 0.006-0.024 microg/ml in vitro and highly effective therapeutic activity at low doses in vivo. Additionally, the results of the post-antibiotic effect of OPC-67683 on intracellular Mycobacterium tuberculosis showed the agent to be highly and dose-dependently active also against intracellular M. tuberculosis H37Rv after a 4-h pulsed exposure, and this activity at a concentration of 0.1 microg/ml was similar to that of the first-line drug rifampicin (RFP) at a concentration of 3 microg/ml. The combination of OPC-67683 with RFP and pyrazinamide (PZA) exhibited a remarkably quicker eradication (by at least 2 mo) of viable TB bacilli in the lung in comparison with the standard regimen consisting of RFP, isoniazid (INH), ethambutol (EB), and PZA. Furthermore, OPC-67683 was not affected by nor did it affect the activity of liver microsome enzymes, suggesting the possibility for OPC-67683 to be used in combination with drugs, including anti-retrovirals, that induce or are metabolized by cytochrome P450 enzymes. CONCLUSIONS: We concluded that based on these properties OPC-67683 has the potential to be used as a TB drug to help combat the unmet needs in TB treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847 · cited 1×
“Genome research of tubercle bacilli has verified this lipid richness, showing there to be almost 250 distinct enzymes involved in the lipid metabolism of tubercle bacilli [30].”
BackgroundClinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
J Antimicrob Chemother 1994; 33: 350–351
O'SHAUGHNESSY, E. M., & DAS, S. S. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.350 · Cited by 3,746
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Cytochrome P-450: Structure, Mechanism, and Biochemistry
de Montellano, O., & Paul, R. (1986) · Medical Entomology and Zoology · Cited by 2,663
Cytochrome P450: Structure, mechanism, and biochemistry
Pryor, W. A. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(96)83807-x · Cited by 1,598
Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects
Guengerich, F. P., Kim, D. H., & Iwasaki, M. (1991) · Chemical Research in Toxicology · doi:10.1021/tx00020a008 · Cited by 1,169
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Global tuberculosis incidence and mortality during 1990-2000.
Dolin, P., Raviglione, M. C., & Kochi, A. (1994) · Europe PMC (PubMed Central) · Cited by 877
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action
Edwards, D. I. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.1.9 · Cited by 606
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
Rahman, A., Korzekwa, K., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994) · PubMed · Cited by 430
Global Tuberculosis Programme, & Disease, L. (1997) · Medical Entomology and Zoology · Cited by 361
Manjunatha, U. H., Boshoff, H., Dowd, C. S., Zhang, L., Albert, T. J., Norton, J. E., Daniels, L., Dick, T., Pang, S. S., & Barry, C. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508392103 · Cited by 331
The global situation of MDR-TB
Espinal, M. A. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00058-6 · Cited by 329
Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., & Chenery, R. J. (1995) · Xenobiotica · doi:10.3109/00498259509061850 · Cited by 298
Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.
Sesardic, D., Boobis, A., Murray, B., Murray, S., Segura, J., de la Torre, R., & Davies, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03686.x · Cited by 278
Pharmacokinetic Interactions of Cimetidine 1987
Somogyi, A., & Muirhead, M. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198712050-00002 · Cited by 191
Inaba, T., Jurima, M., Mahon, W. A., & Kalow, W. (1985) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08231-5 · Cited by 179
Li, A. P., Reith, M. K., Rasmussen, A., Gorski, J. C., Hall, S. D., Xu, L., Kaminski, D. L., & Cheng, L. K. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00071-9 · Cited by 172
Antidepressant Drug Interactions and the Cytochrome P450 System: A Critical Appraisal
Riesenman, C. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb02909.x · Cited by 82
Population Pharmacokinetic Modeling of Pyrazinamide in Children and Adults with Tuberculosis
Zhu, M., Starke, J. R., Burman, W. J., Steiner, P., Stambaugh, J. J., Ashkin, D., Bulpitt, A. E., Berning, S. E., & Peloquin, C. A. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.9.686.34067 · Cited by 77
Broly, F., Libersa, C., Lhermitte, M., et al. (1989) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1989.tb03502.x · Cited by 74
Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401
Stevens, J. C., White, R. B., Hsu, S. H., & Martinet, M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36941-1 · Cited by 48
Cytochrome P450 Monooxygenases and Interactions of Psychotropic Drugs: A Five-Year Update
Shen, W. W. (1995) · The International Journal of Psychiatry in Medicine · doi:10.2190/29np-2xpn-x0me-mqwu · Cited by 48
Inhibition of Human Drug Metabolizing Cytochrome P450 by Buprenorphine.
Umehara, K., Shimokawa, Y., & Miyamoto, G. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.682 · Cited by 46
Self-citationEmoto, C., Yamazaki, H., Iketaki, H., Yamasaki, S., Satoh, T., Shimizu, R. W., Suzuki, S., Shimada, N., Nakajima, M., & Yokoi, T. (2001) · Xenobiotica · doi:10.1080/00498250110052120 · Cited by 25
Cited by
Zhou, Y., Wang, J., Gu, Z., Wang, S., Zhu, W., Aceña, J. L., Soloshonok, V. A., Izawa, K., & Liu, H. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00392 · Cited by 2,808
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Nepali, K., Lee, H.-Y., & Liou, J.-P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00147 · Cited by 629
Metadata
- Authors
- Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-11-28
- Volume
- 3
- Issue
- 11
- Pages
- e466
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W1969586092
- Cited by
- 751
- References
- 28
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.